Generics
Products & dossiers
We develop and manufacture our products after the careful selection and qualification of our partners. Product quality, supply chain stability and sustainability are of key importance to us.
A full list of our dossiers available for in-licensing or in development can be found below.
Dossier list
| Molecule | Originator brand | Indication | Strengths | Administration | Main sector¹ | Type of dossier | Dossier availability | EU Data protection² | Expected launch³ |
|---|---|---|---|---|---|---|---|---|---|
| Caspofungin | Cancidas® by Merck | Antifungal, systemic | 50 mg, 70 mg | Parenteral | Hospital | EU-CTD | Available | Expired | Commercial |
| Anidulafungin | Ecalta® by Pfizer | Antifungal, systemic | 100 mg | Parenteral | Hospital | EU-CTD | Available | Expired | Commercial |
| Micafungin | Mycamine® by Astellas | Antifungal, systemic | 50 mg, 100 mg | Parenteral | Hospital | EU-CTD | Available | Expired | Commercial |
| Rivaroxaban | Xarelto® by Bayer | Anticoagulant | 2.5 mg, 10 mg, 15 mg, 20 mg | Oral | Retail | EU-CTD | Available | Expired | 04.2024 / 01.2026³ |
| Ticagrelor | Brilique® by AstraZeneca | Anticoagulant | 60 mg, 90 mg | Oral | Retail | EU-CTD | Available | Expired | 06.2025 |
| Tafamidis Meglumine | Vyndaqel® by Pfizer | Amyloidosis | 20 mg | Oral | Mixed | EU-CTD | Available | Expired | 11.2026 |
| Tafamidis free acid | Vyndaqel® by Pfizer | Amyloidosis | 61 mg | Oral | Mixed | EU-CTD | Pipeline | 02.2030 | TBD |
| Macitentan | Opsumit® by Actelion | Pulmonary hypertension | 10 mg | Oral | Mixed | EU-CTD | Available | Expired | 12.2026 |
| Isavuconazole | Cresemba® by Basilea | Antimycotic | 100 mg | Oral | Hospital | EU-CTD | Q2’2026 | 10.2027 | 2028⁴ |
| Isavuconazole | Cresemba® by Basilea | Antimycotic | 200 mg | Parenteral | Hospital | EU-CTD | Q2’2026 | 10.2027 | 2028⁴ |
| Nusinersen | Spinraza® by Biogen | Spinal muscular atrophy | 12 mg | Parenteral | Hospital | EU-CTD | Pipeline | 06.2029 | 06.2031 |
| Risdiplam | Evrisdy® by Roche | Spinal muscular atrophy | 60 mg | Oral | Mixed | EU-CTD | Pipeline | 03.2031 | 2036 |
Product List Version: October 2024
_________
¹Main sector is based on average IQVIA sales distribution by Standard Units in Europe
²Expected launch date applies for market entry of generic products in major European countries. Please check specific patent situation in any particular country of interest
³04.2024 referring to 2.5mg and 01.2026 to the rest of the presentations. Legal proceedings ongoing in several countries.
⁴High probability of pediatric extension to 10.2027, taking the launch to 2028.
For further information, please contact: moc.eimehctceles@gnisnecil.amrahp
Disclaimer: None of the products will be offered for sale or supply to countries in which they were affected by valid and effective patents in force.
Interested in in-licensing?
If you are interested in in-licensing our dossiers, please contact us.
For information on our business model of the co-development of generics, click the button below.
